How to report a compounded peptide problem to FDA MedWatch

01

Know when MedWatch is the right channel

FDA describes MedWatch as its medical-product safety reporting program for health professionals, patients, and consumers. Reports can concern prescription and over-the-counter drugs, biologics, combination products, and other regulated products. For compounded peptide-related drugs, relevant issues may include a serious adverse event, suspected contamination, particles, unexpected color, damaged packaging, labeling confusion, concentration problems, temperature concerns, or a medication error.

MedWatch is not emergency care and does not replace contacting the treating clinician, dispensing pharmacist, poison control, or emergency services. Seek prompt medical attention for urgent symptoms. Reporting can follow once immediate safety needs are addressed.

02

Distinguish an adverse event, error, and quality problem

FDA’s voluntary reporting instructions define an adverse event broadly as an adverse outcome suspected to be associated with a medical product. The reporter does not need certainty about cause and effect. Medication-use errors include preventable problems in prescribing, preparation, dispensing, labeling, administration, or monitoring, including a close call that could have caused harm.

A product-quality problem can exist without an injured patient. Examples relevant to compounded injectables may include visible particulate matter, leaking containers, a mismatched label, unclear units, suspected potency problems, or compromised shipping. If an adverse event may be connected to a quality problem, FDA instructs reporters to identify both.

Therapeutic failure is another report category on FDA’s voluntary form. It describes a product that may not have performed as expected; it does not invite a reporter to conclude why. Separate the observed outcome from possible explanations such as product quality, prescribing, preparation, administration, storage, adherence, or the underlying condition.

03

Preserve the information FDA can use

Before discarding packaging, photograph the front and back of the label and the shipping materials. Record the product name, stated active ingredient, strength or concentration, route, container type, beyond-use or expiration date, lot number, prescription number, pharmacy or compounder, prescriber, delivery date, and storage condition when received. Do not send the physical product to FDA unless instructed.

Describe what happened in chronological order: when use began, when the event or defect was noticed, what amount was administered as stated on the prescription, what symptoms or problem occurred, what care was obtained, and what happened after use stopped. Report facts and uncertainty plainly. Avoid guessing at a diagnosis or contaminant.

• →Exact legal name and contact information of the dispensing pharmacy
• →Product label, strength or concentration, and lot number if known
• →Dates, route, and instructions exactly as provided
• →Photos of the product, label, packaging, and shipping condition
• →Clinical records or test dates relevant to a serious event

04

Submit through the FDA pathway

FDA provides an online MedWatch reporting portal. Its instructions also identify Form FDA 3500 for voluntary health-professional reports and Form FDA 3500B for consumers and patients. Follow the current FDA page because forms and portals can change. Keep a copy of the confirmation and the factual timeline you submitted.

If the product came from a pharmacy, also notify the dispensing pharmacy and prescriber so they can evaluate the patient and product. State boards of pharmacy accept complaints about licensed pharmacies, and the appropriate state channel may address licensing or practice issues that are different from FDA’s safety surveillance. Do not assume one report automatically creates every other report.

Consumers can use Form FDA 3500B, while health professionals can use Form FDA 3500; FDA also provides an online portal. Investigational study drugs follow the study protocol’s reporting pathway rather than ordinary voluntary MedWatch reporting. Check the current FDA instructions before submitting because the correct channel depends on the product and setting.

05

Why reports about compounded drugs matter

FDA’s Compounding Incidents Program reviews adverse-event and product-quality complaints to identify possible facility, process, ingredient, medication-error, or handling problems. Multiple reports tied to one facility can signal a process issue; reports involving an ingredient across facilities can suggest a broader ingredient problem. The agency may investigate, communicate a risk, or take other action when evidence warrants.

Reporting patterns have important limits. State-licensed pharmacies that are not outsourcing facilities do not have the same federal adverse-event reporting obligations as 503B outsourcing facilities, so FDA may receive incomplete information. Voluntary reports also cannot establish incidence rates or causation by themselves. They are signals that become more useful when product and event details are complete.

One report may still be valuable when it identifies a specific lot, facility, labeling defect, or unusual event. FDA can request follow-up information and compare reports with inspections, complaints, and other evidence. That process is why complete identifiers and a factual timeline matter more than certainty or speculation from the reporter.

06

Provider and pharmacy practices to verify afterward

Ask the provider and pharmacy how they document complaints, contact affected patients, investigate lots, preserve samples, correct dosing instructions, and communicate recalls. Verify the pharmacy’s current license and whether it is a registered outsourcing facility only if that status is claimed. Neither 503A nor 503B terminology guarantees that a specific product is safe, effective, error-free, or FDA-approved.

If a seller refuses to identify the pharmacy, offers a prescription injectable without a legitimate prescription process, or instructs consumers not to report problems, stop and independently verify the responsible entities. Treatment decisions and symptom evaluation belong with licensed clinicians; regulatory reporting is an additional safety step, not a substitute for care.